Zobrazeno 1 - 10 of 107 pro vyhledávání: '"R Schaafsma"'
2
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study
Autor: Harry R. Koene, Lina van der Straten, J. Martijn Kerst, Sabina Kersting, Arnon P. Kater, Reinier Raymakers, Fatemeh Saberi Hosnijeh, Anton W. Langerak, Mark-David Levin, Mar Bellido, Martijn R. Schaafsma, G. Doreen te Raa, Martine E.D. Chamuleau, Jeanette K. Doorduijn, Marinus H. J. van Oers, Mels Hoogendoorn, Erik W.A. Marijt, Ward Posthuma, Sanne H. Tonino, Fransien de Boer, Michel van Gelder, Johan A. Dobber
Publikováno v: Experimental Hematology, 89, 55. Elsevier
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of kno
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d604aeae92f4f9b8acb5fd120f55dba
https://dspace.library.uu.nl/handle/1874/408766
Zobrazit plný text záznamu
3
Bortezomib before and after high-dose therapy in myeloma
Autor: Marian Stevens-Kroef, M. van Marwijk Kooy, Henk M. Lokhorst, Hans-Walter Lindemann, Anna Potamianou, Gerard M. J. Bos, B. van der Holt, Igor Wolfgang Blau, Annemiek Broijl, Christoph Scheid, Peter Brossart, Pieter Sonneveld, Sonja Zweegman, R. Schaafsma, Sandra Croockewit, Reinier Raymakers, Le Jarari, Ulrich Duehrsen, H Salwender, Jens Hillengass, Dirk Hose, Elias K. Mai, Anna Jauch, Marc-Steffen Raab, Michael Pfreundschuh, Thomas Hielscher, Paula F. Ypma, Marie-Jose Kersten, Katja Weisel, Edo Vellenga, H. Goldschmidt, Uta Bertsch
Publikováno v: Leukemia, 32(2), 383-390. Nature Publishing Group
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell trans
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdac844a1794c65e65c209524742ae10
https://hdl.handle.net/11370/8335fc73-d259-436f-8a52-be9bb4049f03
Zobrazit plný text záznamu
4
Akademický článek
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Autor: Pieter Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Alexandra J. Croockewit, Gregor E.G. Verhoef, Jan J. Cornelissen, Martijn R. Schaafsma, Marinus H.J. van Oers, Pierre W. Wijermans, Petra H.M. Westveer, Henk M. Lokhorst
Publikováno v: Haematologica, Vol 92, Iss 7 (2007)
Background and Objectives The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM).Design a
Externí odkaz: https://doaj.org/article/d70d7d0c55504bca96ffbccecc056912
Zobrazit plný text záznamu
5
Optimising pharmacotherapy in older cancer patients with polypharmacy
Autor: Thijs H. Oude Munnink, M. Wymenga, Elze Vrijkorte, R. Schaafsma, Jennifer de Vries
Publikováno v: European Journal of Cancer Care
European journal of cancer care, 29(1):e13185. Wiley
Objective Polypharmacy is frequent among older cancer patients and increases the risk of potential drug-related problems (DRPs). DRPs are associated with adverse drug events, drug-drug interactions and hospitalisations. Since no standardised polyphar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb2f6e35fddfae77835ee8e640a8091
https://doi.org/10.1111/ecc.13185
Zobrazit plný text záznamu
7
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
Autor: Okke de Weerdt, Harm Sinnige, Niels W.C.J. van de Donk, Monique C. Minnema, Pieter Sonneveld, Mark-David Levin, Saskia K. Klein, Sonja Zweegman, Michel Delforge, Paula F. Ypma, Jules L.L.M. Coenen, Sandra Croockewit, Esther G. M. de Waal, Kon-Siong G. Jie, Henk M. Lokhorst, Bronno van der Holt, R. Schaafsma, Edo Vellenga, Peter A. von dem Borne, Marie José Kersten, Gerard M. J. Bos
Publikováno v: The Lancet Haematology, 5(10), E479-E492. ELSEVIER SCI LTD
The Lancet Haematology, 5(10), e479. Lancet Publishing Group
Lancet Haematology, 5, E479-E492
Lancet Haematology, 5, 10, pp. E479-E492
The Lancet Haematology, 5(10), e479-e492. Lancet Publishing Group
Lancet Haematology, 5(10), E479-E492. Lancet Publishing Group
Lancet Haematology, 5(10), E479-E492. ELSEVIER SCI LTD
Lancet. Haematology, 5(10), e479-e492. Lancet Publishing Group
Lancet Haematology, 5(10), E479-E492
van de Donk, N W CJ, van der Holt, B, Minnema, M C, Vellenga, E, Croockewit, S, Kersten, M J, von dem Borne, P A, Ypma, P, Schaafsma, R, de Weerdt, O, Klein, S K, Delforge, M, Levin, M-D, Bos, G M, Jie, K-S G, Sinnige, H, Coenen, J L LM, de Waal, E G, Zweegman, S, Sonneveld, P & Lokhorst, H M 2018, ' Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial ', The Lancet Haematology, vol. 5, no. 10, pp. e479-e492 . https://doi.org/10.1016/S2352-3026(18)30149-2
Background In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b918400ff671789faa826cd0e7ec5cf9
https://cris.maastrichtuniversity.nl/en/publications/841e85f3-9b20-4389-a589-319ac218bc1d
Zobrazit plný text záznamu
8
Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study
Autor: C.A. Uyl-de Groot, Z. Erjavec, E. (Vera) J. M. Mattijssen, Gerard Vreugdenhil, Kim M. Holtzer-Goor, Eduardus F. M. Posthuma, Simon Daenen, Peter C. Huijgens, P. W. Wijermans, W. G. Peters, H. Visser, M. R. Schaafsma, P. Joosten, S. Wittebol, M. H. J. Van Oers, K. G. van der Hem
Publikováno v: Quality of Life Research, 24(12), 2895-2906. Springer Netherlands
Quality of Life Research, 24(12), 2895-2906. SPRINGER
Holtzer-Goor, K M, Schaafsma, M R, Joosten, P, Posthuma, E F M, Wittebol, S, Huijgens, P C, Mattijssen, E J M, Vreugdenhil, G, Visser, H, Peters, W G, Erjavec, Z, Wijermans, P W, Daenen, S M G J, van der Hem, K G, van Oers, M H J & Uyl-de Groot, C A 2015, ' Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study ', Quality of Life Research, vol. 24, no. 12, pp. 2895-2906 . https://doi.org/10.1007/s11136-015-1039-y
Quality of Life Research, 24(12), 2895-2906. Springer, Cham
Quality of Life Research
Quality of life research, 24(12), 2895-2906. Springer Netherlands
Purpose To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients. Methods HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7058cbb1613db4d1a60c05ddf2daf4
https://doi.org/10.1007/s11136-015-1039-y
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje